Literature DB >> 20361950

Dipeptidyl peptidase-IV in synovial fluid and in synovial fluid mononuclear cells of patients with rheumatoid arthritis.

Lucie Sromova1, Helena Mareckova, Liliana Sedova, Eva Balaziova, Aleksi Sedo.   

Abstract

BACKGROUND: Dipeptidyl peptidase-IV (DPP-IV) enzymatic activity controls biological halftime of multiple local mediators. Its deregulation is associated with pathogenesis of several autoimmune diseases, including rheumatoid arthritis (RA). Although DPP-IV is the canonical representative of the group, a number of other proteins have been shown to have similar enzymatic activity. This study was aimed to identify the molecular source of DPP-IV activity in synovial fluid (SF) and fluid mononuclear cells (FMNC) in patients with RA and osteoarthritis (OA). In addition, the association of DPP-IV and the concentration of stromal cell-derived factor-1alpha (SDF), DPP-IV substrate, were evaluated.
METHODS: DPP-IV activity was measured by the kinetic fluorimetric method. The expression of studied molecules in FMNC and their concentrations in SF were assayed using flow cytometry and ELISA respectively.
RESULTS: DPP-IV activity in SF, dominantly derived from the canonical DPP-IV, does not significantly differ between RA and OA. However, a significantly lower DPP-IV activity and expression in FMNC was found in RA as opposed to OA patients. Negative correlation between SDF concentration in SF and the relative amount of CD3+CD26+ cells was observed.
CONCLUSIONS: We report decreased presence of DPP-IV/CD26 in CD3+ FMNC in RA, which also may participate on impaired balance of SDF concentration in SF. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20361950     DOI: 10.1016/j.cca.2010.03.034

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.

Authors:  Jong-Mi Seong; Jeong Yee; Hye Sun Gwak
Journal:  Br J Clin Pharmacol       Date:  2019-06-04       Impact factor: 4.335

Review 2.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

Review 3.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

4.  Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.

Authors:  Suncica Buljevic; Dijana Detel; Lara Baticic Pucar; Radovan Mihelic; Tomislav Madarevic; Branko Sestan; Jadranka Varljen
Journal:  Rheumatol Int       Date:  2013-07-18       Impact factor: 2.631

5.  Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity.

Authors:  Lucie Sromova; Petr Busek; Liliana Sedova; Aleksi Sedo
Journal:  BMC Musculoskelet Disord       Date:  2015-09-09       Impact factor: 2.362

6.  CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.

Authors:  Oscar J Cordero; Rubén Varela-Calviño; Tania López-González; Cristina Calviño-Sampedro; Juan E Viñuela; Coral Mouriño; Íñigo Hernández-Rodríguez; Marina Rodríguez-López; Bruno Aspe de la Iglesia; José María Pego-Reigosa; José María Pego
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 7.  Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.

Authors:  Jie Huang; Xinxin Liu; Yingying Wei; Xinlu Li; Shupei Gao; Lingli Dong; Xiaoquan Rao; Jixin Zhong
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.